- Yescarta®, axicabtagene ciloleucel is a CD19-directed genetically modified autologous T-cell immunotherapy used for the following indication:
- First-ever FDA-approved CAR T-cell therapy for adult patients with certain types of non-Hodgkin-lymphoma (NHL) who have relapsed or refractory disease after receiving two or more types of treatment.
The Immunotherapy Program at Northside, meets the rigorous requirements of each manufacturer or sponsor, in addition to meeting all accreditation standards through the Foundation for the Accreditation of Cellular Therapy (FACT).
In addition, the program has an efficient CAR T-cell referral and financial approval process. After treatment and follow up care is completed, CAR T-cell patients will return to their primary oncologist.
Please visit immunotherapy clinical trials for a listing of leukemia, relapsed refractory multiple myeloma, diffuse large B-cell lymphoma and other various disease specific immunotherapy trials.